Surface Oncology, Inc. Price & Performance (SURF)

Researchers have developed a novel mini-protein, AKY-1189, that targets Nectin-4 in various tumors, showing minimal impact on healthy tissue. Early human imaging studies are promising, with clinical trials now launching in South Africa and the U.S. to assess its effectiveness in shrinking tumors and improving survival outcomes.1

Toripalimab, combined with chemotherapy, has become the new benchmark for recurrent or metastatic nasopharyngeal carcinoma, significantly improving progression-free and overall survival rates. The therapy, recently approved in the U.S. and China, demonstrated a favorable safety profile, though immune-related side effects were more common compared to standard treatment.2

A major Phase III trial for the mRNA-4157 melanoma vaccine has enrolled over 1,000 high-risk patients worldwide, aiming for completion by 2030. Meanwhile, the BNT111 vaccine, targeting multiple melanoma antigens, is in Phase II testing. These studies reflect growing momentum in cancer immunotherapy research and global collaboration.3